Granowitz Craig B
Insider CIK 1876655 · LXRX SVP, Chief Medical Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2026-02-28 | 2026-03-03 | 202,260 | — | $0 | 404,520 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2026-02-28 | 2026-03-03 | 35,790 | — | $0 | 0 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2026-02-28 | 2026-03-03 | 74,226 | — | $0 | 74,227 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2026-02-28 | 2026-03-03 | 202,260 | — | $0 | 432,528 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | F Tax w/h | 2026-02-28 | 2026-03-03 | 109,098 | $1.47 | $160.4K | 323,430 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2026-02-28 | 2026-03-03 | 74,226 | — | $0 | 230,268 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2026-02-28 | 2026-03-03 | 35,790 | — | $0 | 156,042 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2026-02-12 | 2026-02-17 | 519,920 | — | $0 | 519,920 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2026-02-12 | 2026-02-17 | 346,610 | — | $0 | 346,610 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2025-02-28 | 2025-03-03 | 74,227 | — | $0 | 148,453 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2025-02-28 | 2025-03-03 | 27,917 | — | $0 | 0 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2025-02-28 | 2025-03-03 | 35,790 | — | $0 | 35,790 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2025-02-28 | 2025-03-03 | 27,917 | — | $0 | 75,543 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | F Tax w/h | 2025-02-28 | 2025-03-03 | 65,308 | $0.67 | $43.8K | 120,252 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2025-02-28 | 2025-03-03 | 74,227 | — | $0 | 185,560 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2025-02-28 | 2025-03-03 | 35,790 | — | $0 | 111,333 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2025-02-13 | 2025-02-18 | 910,170 | — | $0 | 910,170 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2025-02-13 | 2025-02-18 | 606,780 | — | $0 | 606,780 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2024-02-28 | 2024-02-29 | 35,790 | — | $0 | 71,580 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2024-02-28 | 2024-02-29 | 27,916 | — | $0 | 27,917 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2024-02-28 | 2024-02-29 | 35,790 | — | $0 | 78,891 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2024-02-28 | 2024-02-29 | 27,916 | — | $0 | 43,101 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | F Tax w/h | 2024-02-28 | 2024-02-29 | 31,265 | $2.62 | $81.9K | 47,626 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2024-02-08 | 2024-02-12 | 222,680 | — | $0 | 222,680 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2024-02-08 | 2024-02-12 | 222,680 | — | $0 | 222,680 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise deriv | 2023-02-28 | 2023-03-01 | 27,917 | — | $0 | 55,833 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | M Exercise | 2023-02-28 | 2023-03-01 | 27,917 | — | $0 | 27,917 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | F Tax w/h | 2023-02-28 | 2023-03-01 | 12,732 | $2.17 | $27.6K | 15,185 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2023-02-09 | 2023-02-13 | 322,110 | — | $0 | 322,110 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2023-02-09 | 2023-02-13 | 107,370 | — | $0 | 107,370 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2022-02-10 | 2022-02-14 | 251,250 | — | $0 | 251,250 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2022-02-10 | 2022-02-14 | 83,750 | — | $0 | 83,750 | SEC↗ |
| LXRX LEXICON PHARMACEUTICALS, I | A Award deriv | 2021-08-02 | 2021-08-03 | 250,000 | — | $0 | 250,000 | SEC↗ |